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New, simple and cost effective UV-spectrophotometric method was developed for the estimation of 
orbifloxacin in pharmaceutical formulation. Orbifloxacin was estimated at 290 nm in 0.5 M hydrochloric 
acid. Linearity range was found to be 1.0-6.0 μg mL–1. The method was tested and validated for various 
parameters according to main guidelines. The proposed method was successfully applied for the 
determination of orbifloxacin in tablets. The results demonstrated that the procedure is accurate, precise 
and reproducible, while being simple, economical and less time consuming. It can be suitably applied 
for the estimation of orbifloxacin in routine quality control and dissolution studies.
Uniterms: Medicines/quality control. Medicines/dissolution. Orbifloxacin/determination. UV 
spectrophotometry/quantitative analysis/validation.
Um método espectrofotométrico novo, simples e de baixo custo foi desenvolvido para a determinação de 
orbifloxacino em formulação farmacêutica. O orbifloxacino foi determinado em 290 nm utilizando ácido 
clorídrico 0,5 M como solvente. O intervalo de linearidade usado foi de 1,0 a 6,0 μg mL–1. O método 
foi testado e validado em vários parâmetros de acordo com os principais guias. O método proposto foi 
aplicado com sucesso para a determinação de orbifloxacino em comprimidos. Os resultados demonstraram 
que este procedimento é exato, preciso e reprodutível, ao mesmo tempo em que é simples, barato e de 
mais rápida execução e pode ser adequadamente aplicado para a determinação de orbifloxacino na rotina 
do controle de qualidade e em estudos de dissolução de comprimidos contendo este fármaco.
Unitermos: Medicamentos/controle de qualidade. Medicamentos/dissolução. Método analítico. 
Orbifloxacino/determinação. Espectrofotometria na região do UV/controle de qualidade/validação.
INTRODUCTION
The fluoroquinolones are a class of compounds 
that comprise a large and expanding group of synthetic 
antimicrobial agents. Orbifloxacin (Figure 1, CAS: 
113617-63-3), namely 1-cyclopropyl-5,6,8-trifluoro-
1,4-dihydro-7-(cis-3,5-dimethyl-1-piperazinyl)-4-
oxoquinoline-3-carboxylic acid, is a new third-generation 
fluoroquinolone antibacterial drug, developed mainly for 
the treatment of gastrointestinal and respiratory infections 
in animals (Nakamura, 1995; Matsumoto et al., 1999a,b; 
Martinez, McDermott, Walker, 2006). It is also used for the 
treatment of skin, soft tissue and urinary tract infections 
particularly in dogs and cats (Davis, Papich, Weingarten, 
2006; Marín et al., 2008). Recent studies have shown that 
orbifloxacin is effective in the treatment of staphylococcal 
pyoderma superficial and deep infections (Scott, Peters, 
Miller Jr, 2006); active against Pseudomonas aeruginosa 
isolated from canine otitis (Mckay et al., 2007), and 
Staphylococcus intermedius responsible for canine skin 
and ear infections (Ganière, Médaille, Etoré, 2004). 
Further, research was also being conducted on widening 
the antibacterial spectrum of orbifloxacin and using it for 
treatment of infection of other animals, such as horses and 
rabbits (Davis, Papich, Weingarten, 2006; Marín et al., 
2008; Haines et al., 2001).
Fluoroquinolones have become an important group, 
particularly for the treatment of infections caused by 
more conventional antibiotic-resistant bacteria (Haines 
et al., 2001). Antimicrobial resistance in bacteria is a 
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phenomenon that has been in constant evolution since the 
introduction of antibiotics. Several factors are known to 
promote bacterial resistance, including poor compliance 
with treatment regimen (DiPersio et al., 1998; Grave, 
Tanem, 1999), prophylactic use of antibiotics (Rantala et 
al., 2004), and the use of antibiotics as growth promoters 
(Boerlin et al., 2001; Emborg et al., 2004) emphasizing 
the importance dosages and treatment appropriate.
For an appropriate dosage of the pharmaceutical 
form orbifloxacin analytical methods should be developed 
and validated. To date, methods described in the scientific 
literature for determination of this analyte in biological and 
other samples involve liquid chromatography with UV 
(Matsumoto et al., 1999a,b; Davis, Papich, Weingarten, 
2006; Morimura et al., 1995a; Morimura et al., 1995b; 
Morimura, Nobuhara, Matsukura, 1997; Morimura et 
al., 1997; Matsumoto et al., 1998a; Matsumoto et al., 
1998b; Matsumoto et al., 1999a,b; Hung et al., 2007; 
British Pharmacopoeia, 2011; Cazedey et al., 2011; 
United States Pharmacopeia 34, 2011; Yu et al., 2012), 
fluorimetry (Marín et al., 2008; Hung et al., 2007; García 
et al., 1999; Kay-Mugford et al., 2002; Schneider, 
Donoghue, 2002; Schneider, Donoghue, 2003; Schneider 
et al., 2005; Schneider, Reyes-Herrera, Donoghue, 
2007; Marín et al., 2007; Chonan et al., 2008; Abd El-
Aty et al., 2009; Elias et al., 2009; Gebru et al., 2009; 
Cho et al., 2010) and/or detection by mass spectrometry 
(Matsumoto et al., 1999a,b; Morimura, Nobuhara, 
Matsukura, 1997a; Morimura et al., 1997; Matsumoto et 
al., 1998a; Matsumoto et al., 1998b; Matsumoto et al., 
1999a,b; Yu et al., 2012; Schneider, Donoghue, 2002; 
Schneider, Donoghue, 2003; Schneider et al., 2005; 
Schneider, Reyes-Herrara, Donoghue, 2007; Johnston, 
Mackay, Croft, 2002; Yamada et al., 2006; Fujita et al., 
2008; Kajita, Hatakeyama, 2008; Saito et al., 2008; Li et 
al., 2009; Santoke et al., 2009; Kantiani, Farré, Barcelo, 
2011; Tang et al., 2012).
Other techniques include the determination of 
orbifloxacin by sequence analysis of samples sensitized 
with luminescent terbium (Llorent-Martínez et al., 2008) 
and by microbiological method (Cazedey, Salgado, 2011).
Also, other ultraviolet analyses have been described 
for fluoroquinolones, such as sparfloxacin (Marona, 
Schapoval, 1999), lomefloxacin (Gomes, Salgado, 2005) 
and gatifloxacin (Salgado, Oliveira, 2005).
The objective of the present study was to develop 
a simple, precise, accurate and economical analytical 
method with the better detection range for estimation 
of orbifloxacin in pharmaceutical formulations and 
dissolution studies.
MATERIAL AND METHODS
Material and reagents
Orbifloxacin reference standard (assigned 
purity 99.8%) was supplied by Sigma-Aldrich. The 
pharmaceutical form tablets were commercially obtained 
and claimed to contain 22.7 mg orbifloxacin (Orbax™ - 
Schering-Plough). All reagents used were analytical grade.
Apparatus
A Shimadzu UV–Vis spectrophotometer, model 
UVmini-1240 was used. UV spectra absorbance of 
reference and sample solutions were recorded in 10 mm 
quartz cells at 290 nm. The solutions were prepared in 
0.5 M hydrochloric acid.
Methods
Analytical method development
Different media were investigated to develop a 
suitable UV-spectrophotometric method for the analysis of 
orbifloxacin in tablets. For selection of media the criteria 
employed were sensitivity of the method, ease of sample 
preparation, solubility of the drug, cost of solvents and the 
applicability of the method to various purposes.
Preparation of standard solutions
The orbifloxacin reference standard solution 
(100.0 μg mL–1) was prepared by accurately weighing 
5.0 mg of orbifloxacin reference in a 50.0 mL volumetric 
flask. The volume was completed with 0.5 M hydrochloric 
acid. This flask was sonicated for 30 min. The above 
solution was diluted in a 10 mL volumetric flask with 
0.5 M hydrochloric acid to obtain a final solution 
containing 3.5 μg mL–1 of orbifloxacin.
Determination of maximum absorption (λmax)
From the standard solution (100.0 μg mL–1) 
FIGURE 1 - Chemical structure of orbifloxacin.
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approximately 3.0 mL was taken and scanned from 200 
to 400 nm with the UV spectrophotometer. The 0.5 M 
hydrochloric acid was used as blank. Orbifloxacin 
presented maximum absorption at 290 nm.
Calibration curve
The calibration curve was constructed by analyzing 
six different concentrations of standard solution, prepared 
on the same day. The range of solutions varied from 1.0 
to 6.0 μg mL–1. All determinations were conducted in 
triplicate.
Assay
To analyze the concentration of orbifloxacin tablets, 
20 tablets were individually weighed and triturated to 
obtain homogeneous mixture. An amount of powder 
equivalent to 5.0 mg of drug was transferred to 50.0 mL 
volumetric flask. The volume was completed with 0.5 M 
hydrochloric acid. The resulting solution was sonicated 
for 30 min to ensure proper solubilization. Aliquots of 
this solution were further diluted with the same solvent, 
in order to obtain a solution with final concentration of 
3.5 μg mL–1. All sample solutions were filtered through 
a quantitative filter. All determinations were conducted 
in triplicate.
Chromatographic conditions
In order to compare the results of the proposed UV 
spectrophotometric method with a reference method, 
the same product batches were analyzed by an HPLC 
technique, which was developed and validated by our 
research group (Cazedey et al., 2011). The mobile phase 
consisted of 5% acetic acid: methanol (80:20, v/v). A flow 
rate of 0.7 mL min-1 was used. Injection volume was set 
at 20 μL. UV detection of the analyte was carried out at 
290 nm.
Dissolution studies
A dissolution test for evaluation of the dissolution 
behavior of orbifloxacin tablets was also developed and 
the profiles were generated. Dissolution samples were 
analyzed with both HPLC (Cazedey et al., 2011) and 
the developed UV spectrophotometric method with UV 
detection at 290 nm. Dissolution studies were carried out 
in USP dissolution apparatus 2 using 0.05 M phosphate 
buffer (pH 6.8) as dissolution medium. The dissolution 
medium was found suitable to ensure sink conditions and 
chemical stability of orbifloxacin. The rotation speed was 
kept at 50 rpm and the volume of the dissolution medium 
was 900 mL. In both methods, the samples were diluted 
with 0.5 M hydrochloride acid to a final concentration of 
2.5 μg mL-1. The results from 60 min, the last time point 
of the dissolution tests performed, were consistent with 
the Assay results. 
Analytical Validation
Selectivity
One of the several ways to assess selectivity is 
a comparison between a matrix without analyte and a 
matrix with the analyte added. In this case, the excipients 
comprising the matrix should not interfere with the assay 
result (ICH, 2005). However, if a matrix without the 
analyte is not available, the selectivity determination can 
be carried out by comparing the slope of two standard 
analytical curves. One curve includes the sample matrix, 
and the other represents a sample without matrix. The 
selectivity is then assessed by comparing these two 
linear regression curve slopes. If they are similar, the 
method is considered selective and the matrix did not 
cause interference in the method (Bonfilio et al., 2012). 
Thus, orbifloxacin standard and sample solutions (1.0 to 
6.0 μg mL–1) were prepared in the selected medium and the 
analytical curves were statistically compared. Additionally, 
the Student’s t-test and F-test were performed to compare 
the orbifloxacin standard and sample absorption values.
Linearity
To establish linearity of the proposed method, six 
series of orbifloxacin standard solution (1.0–6.0 μg mL–1) 
were prepared from the stock solutions and analysed on 
three consecutive days. Least square regression analyses 
were done for the obtained data. ANOVA test (one-way) 
was performed based on the absorbance values observed 
for each pure drug concentration during the replicate 
measurement of the standard solutions.
Precision
Precision was determined by using data from the 
intraday and interday repeatability studies. Same level 
of drug concentration (3.5 μg mL–1), prepared from 
independent stock solution was used for both the studies. 
The solutions of orbifloxacin in six replicates were 
prepared at two different times in a day and studied for 
intraday variation. Same protocol was followed for three 
different days to study interday variation (n = 18). The 
method precision was evaluated by calculating relative 
standard deviation (RSD%).
Accuracy
To determine the accuracy of the proposed method, 
standard addition method was performed. In this study, 
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different concentrations of pure drug (0.8, 1.5 and 
2.2 μg mL–1) were added to a known quantity of sample 
and the total concentration was determined using the 
proposed methods (n = 9). The percent recovery (%R) of 
the added pure drug was calculated as shown in equation 
1(AOAC, 2002):
 100% ×

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where Ct is the total drug concentration measured after 
standard addition; Cu represents the drug concentration 
in the formulation; and Ca, the drug concentration added 
to formulation.
Limit of detection and limit of quantitation
The limit of detection (LOD) and limit of quantitation 
(LOQ) of orbifloxacin by the proposed methods were 
determined using analytical curves. LOD and LOQ were 
calculated as shown in equations 2 and 3 respectively 
(ICH, 2005):
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where σ is the standard deviation of y-intercept of 
regression equation and S is the slope of the calibration 
curve.
Robustness
Robustness of the proposed method was determined 
by changing wavelength from 290 nm to 289 and 291 nm. 
The same concentration (3.5 μg mL–1) was prepared in six 
replicates for each wavelength. The Student’s t tests were 
performed and t-values were determined.
RESULTS AND DISCUSSION
Different media were investigated to develop a 
suitable UV spectrophotometric method for the analysis 
of orbifloxacin in formulation. The solvents tested are 
the following: water, ethanol, ethanol:water (50:50, 
v/v), methanol, 0.1 M hydrochloric acid (HCl), 0.5 M 
hydrochloric acid and 1 M sodium hydroxide aqueous 
(NaOH). All the solutions were sonicated for 30 minutes 
(Table I). These solvents were tested with respect to 
the extraction efficiency. The best solvent to extract 
orbifloxacin was 0.5 M hydrochloric acid with extraction 
efficiency of 102%.
For media optimization various solvents like water, 
methanol, 0.1 M sodium hydroxide, 5% acetic acid 
(HOAc) and 0.5 M hydrochloric acid were investigated. 
Orbifloxacin showed pH dependent UV absorption 
spectra (Table II). This implies that the pH of the 
analytical medium is very important for estimation of 
orbifloxacin. Orbifloxacin UV absorption spectra in alkali 
medium showed various other bands that could be due to 
degradation of the drug. The final decision of using 0.5 
M hydrochloric acid as a media was based on criteria like 
residue generation, sensitivity of the method, cost, ease 
of sample preparation, solubility, and applicability of the 
method.
The λmax of orbifloxacin in 0.5 M hydrochloric acid 
was found to be 290 nm. Apparent molar absorptivity (e) of 
drug, determined by using Beer’s law, was found to be 4.33 
× 104 l mol−1 cm−1 (Table III) , this value was calculated 
according to the standard formulae (Equation 4):
 
bc
A
×
=ε  (4)
where A is the absorbance; c, molar concentration (mol/L) 
and; b, the cell optical length (cm).
In 0.5 M hydrochloride acid, the linearity range 
TABLE I - Extraction rate of orbifloxacin from the pharmaceutical 
dosage form
Solvent % extracted orbifloxacin*
Water ≈ 78
Ethanol ≈ 68
Ethanol: water (50:50, v/v) ≈ 87
Methanol ≈ 89
0.1 M HCl ≈ 90
0.5 M HCl ≈ 102
0.1 M NaOH ≈ 12
*All solutions were sonicated for 30 minutes
TABLE II - Wavelength and absorption of orbifloxacin 
(10.0 μg  mL-1) in different solvents
Solvent Wavelength (λmax) (nm) Absorption
Water 290 0.9934
Methanol 291 1.0313
0.1 M NaOH 288 1.4901
5% HOAc 290 1.1724
0.5 M HCl 290 1.1888
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was found to be 1.0 to 6.0 μg mL–1. The linear regression 
equation obtained was: absorbance at 290 nm = [0.1107 × 
concentration in μg mL–1] - 0.0028; with a regression 
coefficient of 0.9999 (Table III).
Absorption spectrum of pure drug sample was 
matching with the marketed formulation sample in the 
selected medium. The calculated Student’s t-values and 
F-values were found to be less than that of the critical 
values, indicating that statistically there was no significant 
difference between mean absorbance of solutions prepared 
from pure drug sample and marketed formulation sample 
(Table III). Moreover, the analytical curves of orbifloxacin 
standard and sample solutions were compared and 
presented no significant statistical difference (Figure 2). 
Therefore, proposed method is considered selective for 
the orbifloxacin.
Accuracy ranged from 98.04% to 101.58%. The 
excellent mean % recovery values (nearly 100%) and 
its low relative standard deviation values (RSD% < 2.0) 
represent accuracy (Table III) of the UV spectrophotometric 
method.
Precision was determined by studying repeatability 
and intermediate precision. Repeatability results indicate 
TABLE III - Optical characteristics, statistical data of the regression equations and validation parameters for orbifloxacin
Parameter
Optical characteristics
Apparent molar absorptivity (L mol-1 cm-1) 4.33 x 104
Regression analysis
Slope (S.E.a) 0.1107 (0.0006)
Intercept (S.E.a) -0.0028 (0.0008)
Regression coefficient (r) 0.9999
Calculated F-value (critical F-value)b 2215.15 (4.75)
Validation Parameters
Selectivity Fcal (Fcrit)c 0.86 (5,05)
tcal (tcrit)c 1.74 (1.81)
Linearity (μg mL-1) 1.0-6.0
LOD (μg mL-1) 0.04
LOQ (μg mL-1) 0.12
Accuracy - recovery (RSD%) 99.77 (1.78)
Precision (RSD%)d Intraday 1.23
Interday 1.31
Robustness - tcal (tcrit)c 290-289 nm 1.61 (2.18)
290-291 nm 0.36 (2.18)
aStandard error of mean. bTheoretical value of F(4,45) based on one-way ANOVA test at P = 0.05 level of significance. ctcal and 
Fcal are calculated values and tcrit and Fcrit are theoretical values (n = 6) based on paired Student’s t-test and F-test, respectively, at 
P=0.05 level of significance. dRelative standard deviation
FIGURE 2 - Statistical comparison of orbifloxacin standard 
(St) and sample (Sp) analytical curves in the range of 1.0 to 
6.0 μg mL-1.
Sp: y = 0.111x - 0.0049
r = 0.9998
St: y = 0.1107x - 0.0028
r = 0.9999
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the precision under the same operating conditions over a 
short interval of time and inter-assay precision (intraday). 
Intermediate precision expresses the results in different days 
(interday). The precision RSD% values were not more than 
1.5% in all the cases (Table III). RSD values were within the 
acceptable range indicating that this method has excellent 
repeatability and intermediate precision.
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LOD and LOQ, calculated according to the ICH 
(2005) guidelines, were found to be 0.04 µg ml–1 and 0.12 
μg mL–1, respectively.
Variation of wavelengths by ±1 nm did not have any 
significant effect on absorbance (Table III). The Student’s 
t-test values in both cases-variation were not statistically 
significant (tcal < tcrit), indicating that the developed method 
was robust.
The proposed analytical method was applied 
for determination of orbifloxacin in tablets. The assay 
values of orbifloxacin in tablets ranged from 99.99% to 
101.25% with standard deviation not more than 0.66%. 
The estimated drug content with low values of standard 
deviation established the precision of the proposed 
methods. Furthermore, the results, expressed as percentage 
of drug related to label claim, are shown in Table IV. 
Moreover, the same product batches were analyzed by 
an HPLC method (Cazedey et al., 2011) and a Student’s 
t-test was applied. The Student’s t-values did not exceed 
the tabulated value (for five degrees of freedom) indicating 
no significant difference between the methods. In addition, 
the two developed methods were used to evaluate the 
dissolution behavior of orbifloxacin tablets. In both 
methods, the drug could be assayed and the methods were 
compared. Again, no statistical difference was found to the 
HPLC and UV spectrophotometric methods (Table IV).
CONCLUSION
An UV spectrophotometric method was developed, 
validated and applied for the determination of orbifloxacin 
in pharmaceutical dosage form and dissolution tests. 
The developed method was validated as per ICH 
guidelines and was found to be accurate, precise, linear, 
reproducible, robust and selective. No interference from 
any components of pharmaceutical dosage form was 
observed. Furthermore, the method did not present any 
statistically significant difference as compared to the 
HPLC method.
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